Low Apgar score · pregnant women
Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.03
7514 participants
Low
Proportion of participants with best‐corrected visual acuity of 20/40 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with cystoid macular edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs plus corticosteroids may leads to lower proportion of participants with cystoid macular edema 1 week compared with corticosteroids alone (low certainty).
1 finding from 1 review
Time to cessation of treatment · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraocular inflammation measured by anterior chamber cell and flare 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraocular inflammation measured by proportion of participants with corneal edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs plus corticosteroids showed no clear difference in intraocular inflammation measured by proportion of participants with… compared with corticosteroids alone (moderate certainty).
1 finding from 1 review
Ambulation · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in ambulation compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Survival (long term) Over two years · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in survival (long term) Over two years compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Pain reduction · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in pain reduction compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Urinary continence One week after treatment · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in urinary continence One week after treatment compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Local recurrence · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
Quality of life · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients with resolution or improved symptoms at days 3 to 7 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
3 findings from 1 review
RR 1.33 [1.09, 1.62]
5 studies · 1043 participants
Moderate
RR 1.4 [1.08, 1.81]
4 studies · 869 participants
Low
RR 1.12 [0.87, 1.44]
1 study · 174 participants
Moderate
Proportion of patients with resolution or improved symptoms at days 4 to 14 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
2 findings from 1 review
Proportion of patients with resolution or improved symptoms at days 4 to 14 ‐ Co‐treatment with antibiotics · patients with acute sinusitis
Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).
1 finding from 1 review
Adverse events · patients with acute sinusitis
1 finding from 1 review
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review